Contributions
Abstract: EP1285
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
The impact of obesity on outcomes of allogeneic stem cell transplantation (ASCT) is controversial.
Aims
The aim of this study is to evaluate the impact of pretransplant body mass index (BMI) on overall survival (OS),relapse free survival (RFS),non -relapse mortality (NRM),documented infectious complications and graft- versus host disease (GVHD).
Methods
We performed a retrospective study in patients who underwent ASCT from HLA-identical sibling donors between June 2015 and December 2018. Conditioning regimen consisted of Busulfex and Cyclophosphamide (Bu/Cy) or Fludarabine and Busulfex (F/Bu) in myeloid malignancies, TBI or thiotepa-based regimen in lymphoid malignancies and thymoglobuline and cyclophosphamide with or without fludarabine in aplastic anemia. Graft-versus host disease (GVHD) prophylaxis consisted of cyclosporine and short course of methotrexate.
Patients were stratified according to pretransplantation BMI values: underweight (BMI<18 kg/m2 ); normal BMI (BMI 18 -25 kg/m2) ; overweight (BMI 25-30 kg/m2 ); obese( BMI 30 kg/m2 ).
Results
One hundred and nineteen patients were included (71 males and 48 females ).The median age was 34 years (7-49y).Diseases were acute myeloid leukemia (n=37,31% ),acute lymphoblastic leukemia (n=31,26% ),aplastic anemia ( n=27,22.7% ),chronic myeloid leukemia or myeloproliferative neoplasms (n=16,13,5% ),myelodysplastic syndrome (n=4,3.4% ) ,NHL (n=4,3.4%).
According to the pretransplant BMI values,56% of patients have a normal BMI,13% were obese,23% were in overweight and 18% were in underweight.
There was no statistically significant association between pretransplant BMI and incidence of acute or chronic disease,acute infectious complications and relapse rate (p=074,p=0.15 and p=0.93 respectively).
However, obese patients have a significantly lower OS compared with other patients (78% vs 92%, p=0.004 ) without impact on RFS (72% vs 84% )between the two groups with p= 0.37).
The NRM was 12,5 % and it was not statistically different between the four groups(p=0.7)
Conclusion
Pretransplant obesity was associated with inferior OS after ASCT without impacting treatment related complications.
Keyword(s): Obesity, Stem cell transplant, Survival
Abstract: EP1285
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
The impact of obesity on outcomes of allogeneic stem cell transplantation (ASCT) is controversial.
Aims
The aim of this study is to evaluate the impact of pretransplant body mass index (BMI) on overall survival (OS),relapse free survival (RFS),non -relapse mortality (NRM),documented infectious complications and graft- versus host disease (GVHD).
Methods
We performed a retrospective study in patients who underwent ASCT from HLA-identical sibling donors between June 2015 and December 2018. Conditioning regimen consisted of Busulfex and Cyclophosphamide (Bu/Cy) or Fludarabine and Busulfex (F/Bu) in myeloid malignancies, TBI or thiotepa-based regimen in lymphoid malignancies and thymoglobuline and cyclophosphamide with or without fludarabine in aplastic anemia. Graft-versus host disease (GVHD) prophylaxis consisted of cyclosporine and short course of methotrexate.
Patients were stratified according to pretransplantation BMI values: underweight (BMI<18 kg/m2 ); normal BMI (BMI 18 -25 kg/m2) ; overweight (BMI 25-30 kg/m2 ); obese( BMI 30 kg/m2 ).
Results
One hundred and nineteen patients were included (71 males and 48 females ).The median age was 34 years (7-49y).Diseases were acute myeloid leukemia (n=37,31% ),acute lymphoblastic leukemia (n=31,26% ),aplastic anemia ( n=27,22.7% ),chronic myeloid leukemia or myeloproliferative neoplasms (n=16,13,5% ),myelodysplastic syndrome (n=4,3.4% ) ,NHL (n=4,3.4%).
According to the pretransplant BMI values,56% of patients have a normal BMI,13% were obese,23% were in overweight and 18% were in underweight.
There was no statistically significant association between pretransplant BMI and incidence of acute or chronic disease,acute infectious complications and relapse rate (p=074,p=0.15 and p=0.93 respectively).
However, obese patients have a significantly lower OS compared with other patients (78% vs 92%, p=0.004 ) without impact on RFS (72% vs 84% )between the two groups with p= 0.37).
The NRM was 12,5 % and it was not statistically different between the four groups(p=0.7)
Conclusion
Pretransplant obesity was associated with inferior OS after ASCT without impacting treatment related complications.
Keyword(s): Obesity, Stem cell transplant, Survival